Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

64.90USD
27 Jul 2016
Change (% chg)

$0.45 (+0.70%)
Prev Close
$64.45
Open
$64.42
Day's High
$65.11
Day's Low
$64.42
Volume
2,632,737
Avg. Vol
2,353,682
52-wk High
$71.50
52-wk Low
$45.46

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and... (more)

Overall

Beta: 1.49
Market Cap(Mil.): $104,966.60
Shares Outstanding(Mil.): 1,617.36
Dividend: 0.57
Yield (%): 3.51

Financials

  ABBV.N Industry Sector
P/E (TTM): 19.44 36.73 37.52
EPS (TTM): 3.34 -- --
ROI: 18.66 15.28 14.48
ROE: 181.93 16.33 15.65

BRIEF-Abbvie receives U.S. FDA approval of once-daily VIEKIRA XR

* Abbvie receives U.S. FDA approval of once-daily VIEKIRA XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the treatment of genotype 1 chronic Hepatitis C

26 Jul 2016

Samsung Bioepis seeks Europe approval for its Humira copy

SEOUL Biosimilars maker Samsung Bioepis, part of South Korea's top family-run conglomerate Samsung Group [SAGR.UL], said on Monday it is seeking regulatory approval in Europe to sell its copy of AbbVie Inc's rheumatoid arthritis drug Humira.

18 Jul 2016

UPDATE 1-Samsung Bioepis seeks Europe approval for its Humira copy

* European Medicines Agency reviewing Samsung Bioepis' application

18 Jul 2016

Blockbuster hopes grow for Ablynx drug backed by AbbVie

Ablynx's hopes for a potential multibillion-dollar drug were boosted on Thursday by strong clinical trial results in rheumatoid arthritis, vindicating a $175 million bet placed on the product by U.S. pharma group AbbVie in 2013.

07 Jul 2016

BRIEF-Biogen and AbbVie's drug approved in EU

* Biogen and AbbVie's once-monthly zinbryta(tm) (daclizumab) approved in European Union for treatment of multiple sclerosis

05 Jul 2016

BRIEF-Biogen and Abbvie's multiple sclerosis drug approved in EU

* Biogen and Abbvie's once-monthly Zinbryta (Daclizumab) approved in European Union for treatment of multiple sclerosis Source text for Eikon: Further company coverage:

05 Jul 2016

BRIEF-Abbvie announces fourth breakthrough therapy designation granted by FDA

* Abbvie announces fourth breakthrough therapy designation granted by the U.S. Food and drug administration (FDA) for ibrutinib (imbruvica) for chronic graft-versus-host-disease (CGVHD), a rare condition with limited treatment options

29 Jun 2016

S&P 500 ends at seven-month high after Yellen comments

The S&P 500 closed at a 7-month high on Monday as Federal Reserve Chair Janet Yellen painted a mostly upbeat picture of the economy but gave little sense of when a rate hike may be coming. | Video

07 Jun 2016

BRIEF-Abbvie reports 17.93 pct passive stake in Reata as of May 25 - SEC filing

* Abbvie Inc reports 17.93 pct passive stake in Reata Pharmaceuticals Inc as of May 25, 2016 - SEC filing Source text for Eikon: [ID:(http://1.usa.gov/1PeZcPg )] Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

07 Jun 2016

BRIEF-Moody's downgrades AbbVie to Baa2; stable outlook

* Baa2 rating reflects its large scale with a revenues of about $23 billion, its high margins and its strong cash flow

02 Jun 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $124.77 -0.38
Pfizer Inc. (PFE.N) $36.85 +0.02
Novartis AG (NOVN.S) CHF81.80 -0.10
Merck & Co., Inc. (MRK.N) $58.60 +0.24
Roche Holding Ltd. (ROG.S) CHF249.60 +0.30
Roche Holding Ltd. (RO.S) CHF251.75 +1.75
Abbott Laboratories (ABT.N) $43.67 +0.07
Eli Lilly and Co (LLY.N) $83.40 +1.31
Sanofi SA (SASY.PA) €76.71 +0.01

Earnings vs. Estimates